Early-Stage Capabilities

Comment

Enhance data exchange between Public Health & Healthcare Orgs

Listed below are the two capabilities that are recommended for addition to the section 'Capability: Enhance and ease data exchange between public health institutions and provider organizations':

  • Development and use of a federated contact tracing system that could be used to pull data to the State systems and vice versa. This is an infrastructure that is needed for responding to localized, widespread, and multi-state epidemics.
  • Implementing FHIR at Scale Taskforce (FAST) IG including directory services and other use cases, as part of the federal infrastructure, for publishing the FHIR APIs and respective documentation for authentication/authorization, consent management etc.

FHIR Write

This capability is still in its early stages but holds significant promise for the future by enabling more seamless bidirectional integration between systems exchanging data with a FHIR server. Currently, when a bidirectional interface is needed, a hybrid approach is often required. For example, vendors might request healthcare data using FHIR while sending data back into the EMR via direct HL7 interfaces. FHIR write functionality could potentially eliminate the need for such hybrid solutions, depending on the types of data sets supported as a standard.

Public Health

HL7 FHIR Electronic Case Reporting IG (eCR IG) is noted as pilot. There is an opportunity for leveraging these data elements to align case reports with the CDISC standards case report forms that are used in both public health and pharma trials by NIH centers, CROs, and researchers around the world. They are built into RedCap and OpenClinica, and the specifications are available on the CDISC website for other vendors to use. This would enable data aggregation more efficiently.  Such forms could be used with IHE RFD as mentioned previously.  CDISC has worked with NIH and others on standards for different Therapeutic Areas and sample case report forms have been provided for Ebola, Vaccines, Virology, COVID-19 and others including Oncology (various types of cancers), Asthma and Alzheimer’s and Parkinsons’ Diseases. The work was done through the Coalition For Accelerating Standards and Therapies (CFAST) with many different organizations and SMEs including CPath, FDA, NIH, CDISC, TransCelerate and Oxford. These standards and their terminology are required by FDA for submissions of data to support the approval of new therapies.  Why would these not be leveraged as a starting point to accelerate the development and adoption of FHIR for research?

Submitted by:
Catalysis (Rebecca D. Kush, PhD), CDISC (Rebecca Baker, MS, MHA, BSN, RN), and Piosoft (Filippo Napoli, PMP)

Enhance and ease data exchange for research purposes

Research would benefit from leveraging the volumes of great work done through the NIH NCI EVS team to curate and maintain controlled terminology for clinical research. This terminology was developed with the CDISC community and is required by FDA and Japan’s PMDA. This body of knowledge has been available since 2008 and has been growing each year, now supporting foundational research needs as well as over 50 therapeutic areas. The terminology was developed through a consensus-based process involving thousands of volunteers from a variety of different organizations around the world to supports research from protocol and data collection through data tabulation, analysis and reporting. These standards are harmonized globally to be synergistic.  It would save significant time and cost to start with this controlled terminology to support research with USCDI and US Core.

Connecting previously defined data elements for research (as developed by the CDISC community) and their codes within the NCI EVS Metathesaurus to the healthcare coding systems, codes, and labels (aka healthcare terminology) will streamline the path to using FHIR and to achieving interoperability.

Currently the only documents mentioned in the draft Federal FHIR Action Plan are the mCode IG and the Genomics Reporting IG.  

We recommend adding the following FHIR IGs in support of research, there may be additional public health IGs that would be beneficial to highlight.  

We applaud the efforts to leverage and harmonize the standards to benefit health and human services. The Action Plan states the FHIR standard will be essential, and we agree this is a good start. However, leveraging other available and applicable standards, particularly in the case of terminology, will move us all forward faster and perhaps better. Specifically, in the case of research standards, benefits and efficiencies have been proven over the past 25 years in a global research community, including NIH centers and FDA. These terminologies to support core data elements and data elements for over 50 therapeutic areas are mature and are maintained by NCI Enterprise Vocabulary Services. It is inefficient and will not enable interoperability to allow users a choice of terminologies.   To truly reach the goal in a reasonable timeframe, it will be important to leverage this past consensus-based work that is relevant to billions of patients worldwide. Otherwise, it could very well take another 20 years to redo work that has already been done.

Submitted by:
Catalysis (Rebecca D. Kush, PhD), CDISC (Rebecca Baker, MS, MHA, BSN, RN), and Piosoft (Filippo Napoli, PMP)